US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Carlsmed, Inc. - Common Stock (NQ:CARL)

14.27 +0.51 (+3.71%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Carlsmed, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
Company Reaffirms Fiscal Year 2026 Guidance 
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical
From Carlsmed
Via GlobeNewswire
Carlsmed (NASDAQ:CARL) Shares Surge on Q1 Earnings Beat and Raised Full-Year Guidance ↗
Via Chartmill
Topics Earnings
Carlsmed Inc (NASDAQ:CARL) Reports Q4 Revenue Beat and Narrower-Than-Expected Loss ↗
Via Chartmill
News headline image
Carlsmed, Inc. Announces Chief Operating Officer Appointment
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform ↗
Carlsmed (NASDAQ:CARL) outlined its strategy for expanding its personalized spine-surgery platform, citing clinical data, reimbursement changes and a planned cervical product launch as potential... 
Via MarketBeat
Topics Supply Chain
News headline image
Carlsmed Q2 Earnings Call Highlights ↗
Carlsmed (NASDAQ:CARL) reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier, as growth in its aprevo lumbar platform and contributions from its newer cervical... 
Via MarketBeat
Topics Earnings
News headline image
Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures
Centers for Medicare & Medicaid Services (CMS) Fiscal Year 2027 Inpatient Final Rule creates three new Medicare Severity-Diagnosis Related Groups (MS-DRGs), with favorable reimbursement for Carlsmed... 
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed, Inc. To Participate in Upcoming Investor Conferences
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed (CARL) Q1 2026 Earnings Transcript ↗
Carlsmed (CARL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Carlsmed® Reports First Quarter 2026 Financial Results
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed, Inc. To Participate in Upcoming Investor Conferences
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Unveils Custom Cervical Plating Tech ↗
Carlsmed (NASDAQ: CARL) stock rises on news of first personalized cervical plating procedure with its corra system. 
Via Benzinga
News headline image
Carlsmed Announces first corra™ personalized Cervical Plating Procedure
The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfolio 
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting
First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop 
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference
From Carlsmed
Via GlobeNewswire
News headline image
Carlsmed Inc (NASDAQ:CARL) Reports Q3 2025 Revenue Beat and Raises Full-Year Guidance ↗
Carlsmed (CARL) reported strong Q3 2025 results, beating revenue and EPS estimates with 98% YoY growth. The AI spine surgery firm also raised its full-year revenue guidance. 
Via Chartmill
Topics Artificial Intelligence
< Previous 1 2 Next >